Raymond James Financial
SLS icon

Raymond James Financial’s SELLAS Life Sciences SLS Stock Holding History

Raymond James Financial’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,652
Closed -$5.81K – 6488
2025
Q2 		$5.81K Buy
+2,652
New +$4.07K ﹤0.01% 6124

Other funds holding SLS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Raymond James Financial's SLS Position: Q3 2025 in Review

Raymond James Financial sold out of SELLAS Life Sciences (SLS) in Q3 2025, closing a stake of 2,652 shares — an estimated $5.81K sold.

Raymond James Financial first reported a position in SLS in Q2 2025 and held it in 1 quarter. The position peaked at $5.81K in Q2 2025. 94 funds tracked by Wall St. Rank hold SLS as of Q3 2025.

  • Raymond James Financial reported no remaining SELLAS Life Sciences position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 2,652 SELLAS Life Sciences shares in Q3 2025, an estimated $5.81K.
  • Raymond James Financial first reported a position in SELLAS Life Sciences in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's SELLAS Life Sciences position peaked at $5.81K in Q2 2025.
  • 94 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.